期刊
CURRENT OPINION IN PHARMACOLOGY
卷 12, 期 6, 页码 704-709出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2012.06.013
关键词
-
资金
- PhRMA Foundation
- Roy J. Carver Charitable Trust
- Roland W. Holden Family Program for Experimental Cancer Therapeutics
It has been over 20 years since it was first recognized that the function of both normal and oncogenic Has is dependent on the post-translational modification termed farnesylation. Since that time, intense effort has been expended on the development of farnesyltransferase inhibitors as novel anticancer agents. Over 70 clinical trials have now been conducted, with limited efficacy demonstrated. Here we provide an update of the most recently published clinical trials, discuss the use of the RASGRP1/APTX two-gene expression screen to select patients with acute myeloid leukemia for therapy, and report on the latest discoveries related to the targets of prenyltransferase inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据